Podcasts about presidential symposium

The 2025 Presidential Symposium will be held on Blue Bell Campus Tuesday, February 11. Dr. Stephanie Allen, Director of Equity, Diversity and Belonging gives all the details about this year's event, including information on keynote speaker Roberto Clemente Jr.     Recorded and edited by Quinn Szentefrom the College's Sound Recording and Music Technology Program

Join host Chris Leidli as he sits down with Emily Walsh Martin, PhD, and Lynnea Olivarez to preview the most intriguing and promising abstracts presented at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting in Los Angeles. Emily and Lynnea share their thoughts on the breathtaking Presidential Symposium before discussing the rest of the program, including clinical implications, the potential impact on rare diseases, and more! Looking for a curated guide through the Annual Meeting? Check out ASGCT's new Session Paths! These six staff-crafted programs provide pathways for some of the most common Annual Meeting attendee profiles: First-time Attendees Cancer Clinical Science Gene Editing Regulatory + Government Affairs Viral Vectors There's still time to register! Join us at the Annual Meeting in Baltimore or from the comfort of your own home with hybrid registration options! Visit https://annualmeeting.asgct.org/register to learn more and register today.Show your support for ASGCT!: https://asgct.org/membership/donateSee omnystudio.com/listener for privacy information.

Dyana Williams, the 2024 Presidential Symposium keynote speaker, talks to Jared about her legendary career in broadcasting, music activism, and celebrity media strategy. Recorded via Zoom and edited by Ian Meranusfrom the College's Sound Recording and Music Technology Program

Dr. Stephanie R. Allen, Director of Equity, Diversity and Belonging, returns to the podcast to talk about what's in store for the 2024 Presidential Symposium on Diversity running Feb. 13-16, 2024. Recorded by Quinn Szente and edited by Ian Meranusfrom the College's Sound Recording and Music Technology Program

Monday at WCLC 2023 features the Presidential Symposium. In this special WCLC 2023 episode of Lung Cancer Considered, hosts Dr. Narjust Florez and Dr. Stephen Liu talk with Dr. Eric Lim about MARS 2: A Multicentre Randomized Trial Comparing (Extended) Pleurectomy Decortication versus No Radical Surgery for Mesothelioma. Dr. Paula Ugalde, discussant for MARS 2, provides her unique overview and perspective on research presented today. The hosts also talk with Dr. P.C. Yang about the new results presented in the TALENT study of lung cancer screening in Taiwan. Patient advocate Emi Bossio adds her unique perspective. Additionally, Dr. Pasi Janne summarizes his presidential abstract: Osimertinib With/Without Platinum-Based Chemotherapy as First-line Treatment in Patients with EGFRm Advanced NSCLC (FLAURA2) and is joined in a discussion with Emi Bossio, a patient with EGFR lung cancer. Professor Eric Lim is a Consultant Thoracic Surgeon at the Royal Brompton Hospital and Professor of Thoracic Surgery at the National Heart and Lung Institute of Imperial College London. Pan-Chyr Yang, MD, PhD--National Taiwan University College of Medicine and National Taiwan University Hospital, Institute of Biomedical Sciences, Genomics Research Center, Academia Sinica, Taiwan. Paula Ugalde – Dr. Paula Ugalde Figueroa, Thoacic Surgeon, Brigham and Women's Hospital Pasi Jänne is the Director of the Lowe Center for Thoracic Oncology at Dana-Farber Cancer Institute and a Professor of Medicine at Harvard Medical School and the David M. Livingston, MD Chair at Dana-Farber Cancer Institute

In June 2023, Daylon and Arun attended the International Society for Stem Cell Research's (ISSCR) annual meeting in Boston, Massachusetts, and recorded daily episodes discussing highlights of the first day of the meeting. They discuss the pre-meeting workshops, including Arun's own talk on stem cell research in space, as well as highlights from the morning's focus sessions and innovation showcases. They also dive into the Presidential Symposium and the new technologies presented in Plenary II.

Dr. Stephanie Allen, Director of Equity, Diversity and Belonging, stops by to tell us her story and to promote the upcoming Presidential Symposium on Diversity. Recorded and edited by Quinn Szentefrom the College's Sound Recording and Music Technology Program

In deze podcast bespreekt internist-oncoloog Koos van der Hoeven met internist-oncoloog Myriam Chalabi, werkzaam in het Antoni van Leeuwenhoek te Amsterdam de NICHE-2-studie; neoadjuvante immunotherapie bij dMMR-coloncarcinoom. Chalabi presenteerde de studie tijdens een Presidential Symposium op het ESMO Congress 2022. Aan bod komen onder andere waarom de studie is uitgevoerd, hoe en de belangrijkste resultaten.

In this episode Associate Professor Jeffrey Looi and his guests discuss topics including the recent pandemic and other related themes which was presented during the Presidential Symposium hosted at the 2022 RANZCP Congress in Sydney.Associate Professor Jeffrey Looi, MBBS Syd, MD ANU, DMedSc Melb, FRANZCP, AFRACMA, is a clinical academic neuropsychiatrist, in private and public practice, and Head of the Academic Unit of Psychiatry and Addiction Medicine at the Australian National University Medical School. Jeffrey leads the Australian, United States, Scandinavian-Spanish Imaging Exchange (AUSSIE) and the Consortium of Australian-Academic Psychiatrists for Independent Policy and Research Analysis (CAPIPRA). He has received multiple research and leadership awards including: a Fulbright Scholarship and Australian-Davos-Connection Future Summit Leadership Award. He is an co-author on more than 230 peer-reviewed papers, involving UCLA, Karolinska Institute and University of Melbourne.Professor Steve Kisely, Steve is a psychiatrist, addiction and public health physician.  He currently works as a Professor at the University of Queensland and Adjunct Professor in Psychiatry, Community Health and Epidemiology at Dalhousie University in Canada. He is also Director of Research for Addiction & Mental Health Services, Metro South Health. Steve is the author of over 380 peer-reviewed full-length papers, on physical/psychiatric co-morbidity, psychiatric epidemiology, pharmaco-epidemiology & health services research. He has been a principal investigator on grants worth $20.3 million. Steve does not hesitate in using research evidence to challenge accepted dogma and practice. Professor Tarun Bastiampillai, MBBS Adl, BMEDSc Adl, FRANZCP is a consultant psychiatrist and Clinical Professor at both Monash and Flinders University. Tarun is also a member of the Consortium of Australian-Academic Psychiatrists for Independent Policy and Research Analysis (CAPIPRA). He has served in several senior leadership roles, having been appointed SA Department of Health, Executive Director of Mental Health Strategy between 2015 to 2018. He is the recipient of the RANZCP 2020 Margaret Tobin Award for outstanding achievement in administrative psychiatry. He has published his research extensively including within, high-impact journals - JAMA, Lancet and Molecular Psychiatry.Feedback:If you have a topic suggestion or would like to participate in a future episode of Psych Matters, we'd love to hear from you.Please contact us by email at: psychmatters.feedback@ranzcp.orgDisclaimer:This podcast is provided to you for information purposes only and to provide a broad public understanding of various mental health topics.  The podcast may represent the views of the author and not necessarily the views of The Royal Australian and New Zealand College of Psychiatrists ('RANZCP'). The podcast is not to be relied upon as medical advice, or as a substitute for medical advice, does not establish a doctor-patient relationship and should not be a substitute for individual clinical judgement.  By accessing The RANZCP's podcasts you also agree to the full terms and conditions of the RANZCP's Website. Expert mental health information and finding a psychiatrist in Australian or New Zealand is available on the RANZCP's Your Health In Mind Website.

It's Day 3 at the IASLC 2022 World Conference on Lung Cancer! Dr. Narjust Florez hosts pivotal researchers Dr. Enriqueta Felip, Dr. Mariano Provencio, and Dr. Rachael Murray to discuss their top-rated studies. IASLC President Dr. Heather Wakelee also joins in to give insight on how the committee selected these high-ranked abstracts for this year's Presidential Symposium.

Welcome to this episode of Physician's Weekly Podcast,  in collaboration with Physician's Weekly. We have 3 fantastic in-depth interviews for you this week. The European Society of Medical Oncology ended a few days ago and later in this episode,  I had the opportunity to speak with Dr. Javier Cortes, in Barcelona, Spain about his Presidential Symposium late-breaking presentation held at that meeting, in which he revealed the data from the much-anticipated phase 3 DESTINY-Breast03 trial for patients with advanced breast cancer. The results of the antibody-drug conjugate trastuzumab deruxtecan compared head-to-head with the current standard, called TDM1,  were practice-changing, with spectacular efficacy (I am not sure I have ever seen a P-value with 22 zeros) and excellent safety outcomes.Also in this episode, our correspondent Dylan Prentner speaks with pediatrician Umbereen Nehal, who was Chief Medical Officer and Vice President of Medical Affairs for Community Healthcare Network in New York city. In addition, Dr. Nehal led a nationwide campaign as chair of the Task Force of American Muslims for Affordable Health Care that was conducted in conjunction with the White House, where she leveraged community resources to educate and enroll American Muslims in new health coverage options. In recognition of this work, Nehal was honored by an invitation from President Barack Obama to the White House. Dr. Nehal talks with us about how to find the balance of hope and humanism in what she says is a system of perverse incentives.But first, Physician's Weekly speaks with dermatologist Dr Sophie Weatherhead from Newcastle, UK  about their recently published research in phototherapy and psoriasis . Further reading:Watson N, Wilson N, Shmarov F, Zuliani P, Reynolds NJ, Weatherhead SC. The use of psoriasis biomarkers, including trajectory of clinical response, to predict clearance and remission duration to UVB phototherapy. J Eur Acad Dermatol Venereol. 2021 Jul 13. doi: 10.1111/jdv.17519. Epub ahead of print. PMID: 34255884.Let us know what you thought of this week's episode on Twitter: @physicianswkly Want to share your medical expertise, research, or unique experience in medicine on the PW podcast? Email us at editorial@physweekly.com! Thanks for listening!

This week on The ASCO Post Podcast, we'll first hear about a study of the monoclonal antibody sintilimab in combination with pemetrexed and platinum to treat advanced nonsquamous non–small cell lung cancer. Then we'll review the results of the CheckMate 743 trial, which suggest a new standard of care in first-line treatment of unresectable malignant pleural mesothelioma.

Advanced cholangiocarcinoma is associated with a particular impaired survival prognosis. So far targeted therapies with relevant clinical efficacy are missing. isocitrate dehydrogenase 1 (IDH1) mutations are observed in a fraction of patients with cholangiocarcinoma. The ClarIDHy, a global, phase III, randomized, double-blind study of ivosidenib ersus placebo in patients with advanced cholangiocarcinoma with an IDH1 mutation met its primary endpoint. Therefore, ivosidenib is a promising new treatment opportunity in patients with Advanced cholangiocarcinoma harboring an IDH1 mutation. Read the Abstract: https://esmoopen.bmj.com/content/5/2/e000699

30 de setembro de 2019 Cobertura de congressos ESMO 2019: Dr. Bradley J. Monk – Destaques em câncer de ovário do Presidential Symposium Dr. Bradley J. Monk comenta três estudos em câncer de ovário apresentados no Presidential Symposium da ESMO 2019: terapia com niraparibe em pacientes com câncer de ovário avançado recentemente diagnosticadas (PRIMA/ENGOT-OV26/GOG-3012 study), o estudo de fase III PAOLA-1/ENGOT-ov25 com olaparibe + bevacizumabe como terapia de manutenção em pacientes com câncer de ovário avançado recentemente diagnosticadas, tratadas com quimioterapia à base de platina + bevacizumabe, e o estudo VELIA/GOG-3005 com a integração de veliparibe à quimioterapia e manutenção em mulheres com carcinoma seroso de alto grau de origem ovariana, trompa de Falópio ou origem peritoneal primária.

This week, we review two studies from a Presidential Symposium at ESMO focusing on the efficacy of PARP inhibitors in patients with newly diagnosed ovarian cancer.Coverage of stories discussed this week on ascopost.com:ESMO 2019: Studies Show PARP Inhibitors Improve Survival, Reduce Risk of Disease Recurrence or Death in Newly Diagnosed Ovarian Cancer

Osimertinib vs comparator EGFR-TKI as first-line treatment for EGFRm advanced NSCLC (FLAURA): Final overall survival analysis. The phase III trial Osimertinib vs comparator EGFR-TKI as first-line treatment for EGFRm advanced NSCLC (FLAURA) showed a significant increase in progression free survival. In the now available finale survival analysis also the overall survival showed a statistical significant increase. Expert: Suresh S. Ramalingam, Winship Cancer Institute of Emory University, Atlanta, GA

The present podcast gives a short summary of the PAOLA-1 trial investigating the addition of Olaparib to bevacizumab as maintenance therapy in patients with newly diagnosed, advanced ovarian cancer treated with platinum-based chemotherapy plus bevacizumab. Expert: Isabelle L. Ray-Coquard Affiliation: Centre Leon Bèrard, Université Claude Bernard Lyon, Groupe d'Investigateurs Nationaux pour l'Étude des Cancers de l'Ovaire (GINECO), Lyon, France

The IMpassion130 trial was a global, randomized, double-blind, Phase III study of Atezolizumab + nab-paclitaxel vs. placebo + nab-paclitaxel in treatment naïve locally advanced or metastatic triple negative breast cancer patients. Here, progression free survival was statistically significantly longer in patients treated with the combination of Atezolizumab + nab-paclitaxel compared to placebo + nab-paclitaxel. The side effect profile was favorable as no unexpected toxicities were observed in the intervention compared to the control arm. In this podcast, Prof. Schmid provides insight on the response rate as well as the preliminary survival analysis of IMpassion130. Further possible biomarkers and the impact of the results on the treatment standard in breast cancer are discussed. Read the full Abstract on the ESMO Open website: https://esmoopen.bmj.com.

Radiotherapy to the primary tumor has been a controversially discussed intervention in patients with newly diagnosed metastatic prostate cancer. Results of the STAMPEDE trial indicate that overall no survival advantage can be achieved by the addition of radiotherapy however subgroups might actually have a benefit. Here, patients with low volume, oligometastatic disease were shown to benefit in a predefined subgroup analysis. In this podcast, Dr. Parker provides insight on the practice changing impact of the STAMPE trial and gives an outlook what is next on the horizon in metastatic prostate cancer therapy. Read the full Abstract on the ESMO Open website: https://esmoopen.bmj.com/

Marc Schuster, Associate Professor of English, chats with Rose Makofske, Director of Equity and Diversity/Title IX Coordinator, about the upcoming Presidential Symposium on Diversity.

Michele Cuomo, Dean of the Arts and Humanities Division, chats with the winners of the Montgomery County Community College Presidential Symposium Poetry contest.

Prof Marivi Mateos (University Hospital of Salamanca, Salamanca, Spain), Prof Meletios Dimopoulos (University of Athens, Athens, Greece), Prof Paul Richardson (Dana-Farber Cancer Institute, Boston, USA) and Prof Phillip McCarthy (Roswell Park Cancer Institute, New York, USA) discuss the latest data on multiple myeloma from EHA 2016. Presented during the Presidential Symposium, the POLLUX data was an open-label, randomised PIII study of daratumumab, lenalidomide, and dexamethasone (DRd) versus lenalidomide and dexamethasone (Rd) in relapsed or refractory multiple myeloma (RRMM). Prof Meletios Dimopoulos outlines one of the key presentations from EHA 2016, showing a 63% reduction in the risk of progression/death and a doubling of CR for DRd vs Rd. The addition of daratumumab also increased the ORR for DRd vs Rd (93% vs 76%) and improved median PFS which was 18.4 months for patients receiving Rd and has not yet been reached in the daratumumab arm. This data led the panel to pose the question whether this could be considered “the most active treatment in this setting”, and with positive combination data also discussed from the CASTOR trial, concluding that combination therapies are having a positive impact on the MM landscape. A note of caution was expressed for triple refractory patients where combination therapy fails, so although treatment seems to be heading in the right direction, it has not yet answered some important and remaining clinical questions. Another study discussed looked at a meta-analysis of OS in patients with MM treated with lenalidomide (LEN) maintenance after high-dose melphalan and autologous stem cell transplant (ASCT). This large study demonstrated that LEN maintenance significantly prolonged OS vs placebo/no maintenance post ASCT, including in patients who achieved CR. This being the case, there are questions remaining for patients receiving this treatment with high risk genetic abnormalities. These trials show the therapeutic advances coming from EHA 2016, building anticipation for the future progress that can be made for treating patients with multiple myeloma.

Dr Haffty talks to ecancertv at ASTRO 2015 about some of the research highlights of the meeting including the Presidential Symposium, which looks at the role of radiation therapy in the multidisciplinary management of gastrointestinal malignancies. In the interview he also outlines some of the recent research that he has been involved with and talks about the use of radiation oncology in treating breast cancer. In addition, Dr Haffty discusses some of the initiatives and programmes that ASTRO has initiated to raise the bar of radiation oncology yet further.

Epilepsy.com Editor-In-Chief Dr. Joseph Sirven interviews Dr. Elson So, past president of the American Epilepsy Society, about his 2014 Presidential Symposium. The topic of the symposium was "Electrophysiological Biomarkers: Spatial and Temporal Prediction of Epilepsy and Seizures." An international competition using the wisdom of crowds has developed computer algorithms to detect, predict, and ultimately prevent epileptic seizures. Winners were announced at the AES 68th Annual Meeting in Seattle during the Presidential Symposium. This content will be created through a partnership between the Epilepsy Foundation and American Epilepsy Society.